331 related articles for article (PubMed ID: 37291377)
21. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
23. Treatment of brain metastases in patients with HER2+ breast cancer.
Bravo Marques JM
Adv Ther; 2009 Jul; 26 Suppl 1():S18-26. PubMed ID: 19669638
[TBL] [Abstract][Full Text] [Related]
24. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of breast cancer subtypes in elderly patients.
Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
[TBL] [Abstract][Full Text] [Related]
26. Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
Liede A; Sebby W; Miriyala AKR; Potluri R; Mazumder D; Ghosh A; Papademetriou E; Kilpatrick R; Tyczynski JE
BMC Cancer; 2023 Jan; 23(1):78. PubMed ID: 36690978
[TBL] [Abstract][Full Text] [Related]
27. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thézenas S; Jacot W
Int J Cancer; 2016 Nov; 139(10):2299-311. PubMed ID: 27464303
[TBL] [Abstract][Full Text] [Related]
28. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
Fabi A; Malaguti P; Vari S; Cognetti F
J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
Iwata H; Narabayashi M; Ito Y; Saji S; Fujiwara Y; Usami S; Katsura K; Sasaki Y
Int J Clin Oncol; 2013 Aug; 18(4):621-8. PubMed ID: 23011099
[TBL] [Abstract][Full Text] [Related]
30. CNS complications of breast cancer: current and emerging treatment options.
Kaal EC; Vecht CJ
CNS Drugs; 2007; 21(7):559-79. PubMed ID: 17579499
[TBL] [Abstract][Full Text] [Related]
31. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
32. Risk factors and survival outcomes in patients with brain metastases from breast cancer.
Minisini AM; Moroso S; Gerratana L; Giangreco M; Iacono D; Poletto E; Guardascione M; Fontanella C; Fasola G; Puglisi F
Clin Exp Metastasis; 2013 Dec; 30(8):951-6. PubMed ID: 23775210
[TBL] [Abstract][Full Text] [Related]
33. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
34. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
35. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
Dong R; Ji J; Liu H; He X
Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
[TBL] [Abstract][Full Text] [Related]
36. Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.
Tam M; Narayana A; Raza S; Kunnakkat S; Golfinos JG; Parker EC; Novik Y
Med Oncol; 2014 Feb; 31(2):832. PubMed ID: 24390418
[TBL] [Abstract][Full Text] [Related]
37. Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review.
Bhogal T; Cameron D; Palmieri C
Breast; 2022 Jun; 63():85-100. PubMed ID: 35344688
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH
Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives.
Passalacqua MI; Ciappina G; Di Pietro M; Spagnolo CC; Squeri A; Granata B; Muscolino P; Santarpia M
Transl Cancer Res; 2023 Nov; 12(11):3179-3197. PubMed ID: 38130295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]